Namwiwat Medical vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Namwiwat Medical (NAM.BK)

Q3 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

August 202621 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Latest21 Jul – 29 Sep 2026

▲4

NAM pushes overseas expansion and new products as Q2 profit jumps

Italy subsidiary opens Europe, Indonesia base planned NAM set up a fully owned subsidiary in Italy to sell into Europe, and is weighing direct investment in Indonesia after starting assembly there. Foreign sales are only about 5% of revenue now, so success would add a new growth source beyond Thailand.
This is the main new force behind NAM's growth story this period.
PTT purchase deal for enzymatic cleaning solution PTT signed a purchase agreement for NAM's multi-enzyme medical instrument cleaning solution, which has passed international testing. A big local partner buying the product secures orders, cuts Thailand's reliance on imports, and supports NAM's sales and reputation.
A concrete new order from a major partner directly supports revenue.
Q2 profit nearly triples, H2 seen stronger Second-quarter profit rose to 29.5 million baht from 12.5 million a year earlier, and management expects faster growth in the second half on government spending and overseas sales, with margins helped by lower production costs. Note first-half profit still fell year-on-year.
Earnings are the clearest evidence of whether the growth plans are working.
Five-pillar strategy targets 380m baht profit by 2028 NAM laid out five growth engines: wider product range, brand building, overseas expansion via Malaysia and Italy subsidiaries plus an Indonesia assembly base, partnerships, and cost control. It targets 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028, backed by 150 million baht capex.
The strategy and long-term targets frame how the new expansion is meant to pay off.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.